Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes

Keyphrases

• Improved Outcomes 100%
• Bladder Cancer 100%
• Urothelial Carcinoma 100%
• Genomic Heterogeneity 100%
• Tumor Heterogeneity 66%
• Drug Resistance 33%
• Tumor Cells 33%
• Patient Survival 33%
• Cellular Level 33%
• Molecular Alterations 33%
• Multiple Levels 33%
• Tumor Metastasis 33%
• Morphological Characteristics 33%
• Response to Chemotherapy 33%
• Histological Analysis 33%
• Targeted Treatment 33%
• Tumor Tissue 33%
• Monotherapy 33%
• Molecular Analysis 33%
• Variability in Response 33%
• Combination Treatment 33%
• Survival Outcomes 33%
• Heterogeneous Distribution 33%
• Tumor Progression 33%
• Poor Survival 33%
• Muscle-invasive 33%
• Transcriptional Level 33%
• Metastatic Urothelial Cancer 33%
• Subclone 33%
• Clinical Drugs 33%
• Cell Clones 33%
• Drug Relapse 33%
• Drug Design 33%
• Genetic Events 33%
• Clinical Trial Design 33%
• Therapeutic Targeting 33%
• Variant Histology 33%
• Inter-patient 33%
• Response to Immunotherapy 33%
• Driver Events 33%
• Treatment Lines 33%
• Mutation Profile 33%
• Intertumoural Heterogeneity 33%

Medicine and Dentistry

• Transitional Cell Carcinoma 100%
• Bladder Cancer 100%
• Genetics 100%
• Tumor Cell 33%
• Metastatic Carcinoma 33%
• Immunotherapy 33%
• Clinical Trial 33%
• Tumor Progression 33%
• Morphological Trait 33%
• Drug Resistance 33%
• Monotherapy 33%
• Urothelial Cancer 33%
• Tumor 33%
• Tumour Heterogeneity 33%
• Histology 33%
• Chemotherapy 33%

Biochemistry, Genetics and Molecular Biology

• Genomics 100%
• Genetics 50%
• Drug Resistance 50%
• Clinical Trial 50%
• Tumor Progression 50%
• Cell Clone 50%
• Morphological Trait 50%
• Drug Development 50%